Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Shaw, A Kim, D Nakagawa, K Seto, T Crinó, L Ahn, M De Pas, T Besse, B Solomon, B Blackhall, Fiona H
Shaw, A
Kim, D
Nakagawa, K
Seto, T
Crinó, L
Ahn, M
De Pas, T
Besse, B
Solomon, B
Blackhall, Fiona H
Citations
Altmetric:
Abstract
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown.
Description
Date
2013-06-20
Publisher
Collections
Keywords
Type
Article
Citation
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013, 368 (25):2385-94 N Engl J Med